Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 11/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.38 |
| ▸ | AXL | P30530 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.37 |
| ▸ | MERTK | Q12866 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4768297 | 0.92 | ALDH1A1 (0.37) | ALDH1A1MEN1LMNAKMT2AUSP2 | |
| SCHEMBL13981718 | 0.91 | MET (0.41) | METKDRBRAFALDH1A1LMNA | |
| SCHEMBL4766821 | 0.89 | MET (0.45) | METALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL4771027 | 0.88 | MET (0.44) | METALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL4765274 | 0.87 | MET (0.45) | METALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL4768368 | 0.85 | MET (0.42) | METALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL4765467 | 0.85 | MET (0.42) | METALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL4774765 | 0.85 | MET (0.43) | METPLA2G7AXLTYRO3MERTK | |
| SCHEMBL4774406 | 0.84 | MET (0.41) | METKDRMEN1KMT2AUSP2 | |
| SCHEMBL4765507 | 0.81 | MET (0.47) | METALDH1A1MEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329716-B2 | e.g. N4-{3-Fluoro-4-[(3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}pyrimidine-2,4-diamine; cardiovascular disorders; lower the blood pressure, increase coronary-perfusion, relax vessels; antitumor agent, metastasis; side effect reduction | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-11 | — | — | US | disclosed |
| US-8329716-B2 | e.g. N4-{3-Fluoro-4-[(3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}pyrimidine-2,4-diamine; cardiovascular disorders; lower the blood pressure, increase coronary-perfusion, relax vessels; antitumor agent, metastasis; side effect reduction | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-11 | — | — | US | disclosed |
| US-8329716-B2 | e.g. N4-{3-Fluoro-4-[(3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}pyrimidine-2,4-diamine; cardiovascular disorders; lower the blood pressure, increase coronary-perfusion, relax vessels; antitumor agent, metastasis; side effect reduction | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-11 | — | — | US | disclosed |
| EP-1751153-B1 | HETARYLOXY-SUBSTITUTED PHENYLAMINO PYRIMIDINES AS RHO KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2008-12-03 | — | — | EP | disclosed |
| US-20080139595-A1 | Hetaryloxy-Substituted Phenylamino Pyrimidines as Rho Kinase Inhibitors | BAYER HEALTHCARE AG (DE) | 2008-06-12 | — | — | US | disclosed |
| US-20080139595-A1 | Hetaryloxy-Substituted Phenylamino Pyrimidines as Rho Kinase Inhibitors | BAYER HEALTHCARE AG (DE) | 2008-06-12 | — | — | US | disclosed |
| US-20080139595-A1 | Hetaryloxy-Substituted Phenylamino Pyrimidines as Rho Kinase Inhibitors | BAYER HEALTHCARE AG (DE) | 2008-06-12 | — | — | US | disclosed |
| WO-2005097790-A1 | HETARYLOXY-SUBSTITUTED PHENYLAMINO PYRIMIDINES AS RHO KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139595-A1 | Hetaryloxy-Substituted Phenylamino Pyrimidines as Rho Kinase Inhibitors | TNK2, ROCK1, ROCK2 | MET 1524/4885KDR 451/4885BRAF 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.